Inhibitor Therapeutics, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020
November 16, 2020 at 09:06 am EST
Share
Inhibitor Therapeutics, Inc. announced earnings results for the third quarter ended September 30, 2020. For the third quarter, the company announced operating loss was USD 302,774 compared to USD 682,921 a year ago. Net loss was USD 302,767 compared to USD 678,548 a year ago. For the nine months, operating loss was USD 1.003 million compared to USD 2.110 million a year ago. Net loss was USD 1.002 million compared to USD 2.097 million a year ago.
Inhibitor Therapeutics, Inc. is a pharmaceutical development company. The Company is focused on developing and commercializing therapeutics based on already approved active pharmaceuticals that have patent-protected methods of use and/or methods of delivery for patients with certain cancers and certain non-cancerous proliferation disorders. Its primary focus is on the development of therapies initially for basal cell carcinoma (BCC), prostate and lung cancers in the United States utilizing itraconazole, a drug approved by the United States Food and Drug Administration (FDA) to treat fungal infections. The Company has developed intellectual property and know-how related to the treatment of cancer patients using itraconazole. The Company's intellectual property in the form of issued United States patents includes treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors, and treatment of lung cancer using hedgehog pathway inhibitors.
INHIBITOR THERAPEUTICS, INC. 
